



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
--------------------	-------------	-----------------------	------------------

08/844,731 04/21/97 DRUD

8 05/16-01P3

EXAMINER

MCGREGOR AND ADLER
8011 CANDLE LANE
HOUSTON TX 77071

A3011/0217

SPART UNIT, C

PAPER NUMBER

1302

DATE MAILED:

02/17/98

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

- ☐ Responsive to communication(s) filed on _____
- ☐ This action is FINAL.
- ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

- ☒ Claim(s) 1-18 is/are pending in the application.
Of the above, claim(s) _____ is/are withdrawn from consideration.
- ☐ Claim(s) _____ is/are allowed.
- ☒ Claim(s) 1-18 is/are rejected.
- ☐ Claim(s) _____ is/are objected to.
- ☐ Claim(s) _____ are subject to restriction or election requirement.

Application Papers

- ☒ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) _____
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

- ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- ☒ Notice of Reference Cited, PTO-892
- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- ☐ Interview Summary, PTO-413
- ☒ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

(X) Notice to comply with
Requirements for Patent
Sequence disclosures.

--SEE OFFICE ACTION ON THE FOLLOWING PAGES--

SERIAL NUMBER 08/844731
Art Unit 1302

As per 37 CFR 1.126 the claim numbered "14" after claim 17 has been re-numbered --claim 18--.

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

"A person shall be entitled to a patent unless -
(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States."

2. Claims 1-5, 6-7 are rejected under 35 U.S.C. § 102 (b) as being anticipated by Cummins, Jr. (U.S. Patent 5019382).

See col. 4, lines 19-36, col. 5, lines 50-55, col. 6, lines 12-26, col. 13, and the claims. Such disclosure meets the claims.

3. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

SERIAL NUMBER 08/844731

Art Unit 1302

4. Claim 5 is rejected under 35 U.S.C. 103 as being unpatentable over Cummins, Jr. (U.S. Patent 5019382). The disclosure is the same as above as discussed for claim 1. The patent does not disclose an alternate day dosing. However, it does show that a daily dosage is possible, as a single dosage or as divided and administered in a multiple daily dose regimen. The reference also teaches a staggered regimen of 1-3 days per week or month as an alternative to daily dosing. See col. 5, lines 50-55. With such a flexibility as taught by the reference, and since it is common knowledge in the art to employ such a regimen instead of continuous dosing, for a variety of reasons such as, toxicity, the condition of the patient, patient reaction and amelioration of the disease condition, etc., it would have been obvious to one of ordinary skill in the art to adopt an alternate day dosing and administer IFN as shown by Cummins for MS.

5. Claims 1-20 are rejected under 35 U.S.C. 103 as being unpatentable over Cummins, Jr. (U.S. Patent 5019382) in view of Shibutani et al. (Iyakuin Kenkyu, vol. 18(4), pp. 571-82, 1987) and abstracts of WO 94/20122, Gross et al. and Giron et al.

The disclosure for the patent is as discussed above. The whole range of dosages claimed by the instant invention is not shown. However, the Shibutani abstract indicates that IFN toxicity studies with rats showed that it was tolerated well. Therefore it would have been obvious to one of ordinary skill in the art to administer dosages higher

than that shown in the patent with the reasonable expectation that such doses would not produce toxicity side-effects in humans. It would also have been obvious to employ such an alternate day dose regimen instead of continuous dosing, for a variety of reasons such as, toxicity, the condition of the patient, patient reaction and amelioration of the disease condition, etc. The references also do not disclose the prevention or treatment of diabetes. However, in view of the disclosure of the abstracts that show that it was already known in the art at the time the invention was made that interferon prevented the onset of diabetes, the subject matter as a whole would have been obvious to the person of ordinary skill in the art at the time the invention was filed.

6. Claims 1-7 are provisionally rejected under 35 U.S.C. § 101 as claiming the same invention as that of claims 1-7 of copending application Serial No. 08/631470. This is a *provisional* double patenting rejection since the conflicting claims have not in fact been patented.

7. Claims 8-18 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-18 of copending application Serial No. 08/631470 in view of the abstracts of WO 94/20122, Gross et al. and Giron et al. Although the conflicting claims are not identical, they are not patentably distinct from each other because the subject matter of these claims would have been obvious in view of the abstracts that show that it was already known in the art

SERIAL NUMBER 08/844731

Art Unit 1302

at the time the invention was made that interferon prevented the onset of diabetes. [Filing date accorded to the claims 8, 12 and 16 reciting diabetes mellitus (prevention, etc.) is 4/15/96].

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

8. The obviousness-type double patenting rejection is a judicially established doctrine based upon public policy and is primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent not patentably distinct from claims in a first patent. *In re Vogel*, 164 USPQ 619 (CCPA 1970). A timely filed terminal disclaimer in compliance with 37 C.F.R. § 1.321(b) would overcome an actual or provisional rejection on this ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 C.F.R. § 1.78(d).

9. Claims 8-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Throughout the specification both "IFN" and "INF" are used as abbreviations. It is urged that one form be used to avoid confusion. Also in order that abbreviations be used in claims 12, 16 and 17, claim 2 should show IFN- α (or INF- α) in parenthesis after the term 'alpha-interferon'.

In claims 8 and 16, it is unclear what is being covered by the terms "at-risk population". What kind of person does

SERIAL NUMBER 08/844731
Art Unit 1302

this terminology cover. Does prior art define this person?
Note that the specification does not give any description of
this patient.


10. The oath or declaration is defective. A new oath or
declaration in compliance with 37 CFR 1.67(a) identifying
this application by application number and filing date is
required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

It does not identify the parent applications on which
priority is claimed pursuant to 35 USC 120.

NOTE

Any inquiry concerning this communication should be directed
to Examiner C. Sayala at telephone number (703) 308-3035.
Any inquiry of a general nature or relating to the status of
this application should be directed to the Group
receptionist whose telephone number is (703) 308-0661. The
group fax number is (703) 305-3601.


C. Sayala
Primary Examiner
Group 1300.